Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
P2RX7 Biologics Sequence Review Report 2026: P2X purinoceptor 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
P2RX5 Biologics Sequence Review Report 2026: P2X purinoceptor 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
P2RX4 Biologics Sequence Review Report 2026: P2X purinoceptor 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
P2RX3 Biologics Sequence Review Report 2026: P2X purinoceptor 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
P2RX2 Biologics Sequence Review Report 2026: P2X purinoceptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
P2RX1 Biologics Sequence Review Report 2026: P2X purinoceptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RX1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
OXER1 Biologics Sequence Review Report 2026: Oxoeicosanoid receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OXER1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NTF4 Biologics Sequence Review Report 2026: Neurotrophin-4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NTF4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NTF3 Biologics Sequence Review Report 2026: Neurotrophin-3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NTF3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRP2 Biologics Sequence Review Report 2026: Neuropilin-2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRP1 Biologics Sequence Review Report 2026: Neuropilin-1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
NRG4 Biologics Sequence Review Report 2026: Pro-neuregulin-4, membrane-bound isoform Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NRG4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.